A real life study assessing sanger sequencing resistance at failure and retreatment efficacy of NS5A failing patients-Italian VIRONET‐C

At a glance
Trial Overview
Trial Details
- Other Details
- Related Drugs
Interventions
Results
- Publications
Authors
Trial History
References

Trial Profile

A real life study assessing sanger sequencing resistance at failure and retreatment efficacy of NS5A failing patients-Italian VIRONET‐C

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary) ; Velpatasvir (Primary)
Indications Hepatitis C
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

29 Aug 2020 Results presented at The International Liver Congress 2020
24 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com